Faculty Collaboration Database

HPV16 E6 seropositivity among cancer-free men with oral, anal or genital HPV16 infection. Papillomavirus Res 2016 Dec;2:141-144

Date

02/28/2017

Pubmed ID

28239675

Pubmed Central ID

PMC5322843

DOI

10.1016/j.pvr.2016.07.003

Scopus ID

2-s2.0-84980317614 (requires institutional sign-in at Scopus site)   8 Citations

Abstract

Antibodies against the Human papillomavirus 16 (HPV16) E6 oncoprotein appear years prior to clinical diagnosis of anal and oropharyngeal cancer, but whether they develop around the time of HPV infection is unclear. Serum samples from 173 cancer-free men from the Human Papillomavirus Infection in Men (HIM) Study were tested for HPV antibodies and DNA. HPV16 E6 seropositivity was low among men with oral HPV16-infection (1/28; 3.6%, 95%CI=0.0%-18.4%), anal HPV16-infection (1/61; 1.6%, 95%CI=0.0%-8.8%), and 24-month persistent genital HPV16-infection (1/84; 1.2%, 0.0-6.5%). This suggests E6 seroconversion may not occur around the time of oral, anal, or genital HPV16 acquisition.

Author List

Beachler DC, Waterboer T, Pierce Campbell ChM, Ingles DJ, Kuhs KA, Nyitray AG, Hildesheim A, Pawlita M, Kreimer AR, Giuliano AR

Author

Alan Nyitray PhD Associate Professor in the Psychiatry and Behavioral Medicine department at Medical College of Wisconsin